[EN] MACROCYCLIC COMPOUNDS AS TRK KINASES INHIBITORS<br/>[FR] COMPOSÉS MACROCYCLIQUES EN TANT QU'INHIBITEURS DE KINASES TRK
申请人:FOCHON PHARMACEUTICALS LTD
公开号:WO2019184955A1
公开(公告)日:2019-10-03
Provided are certain TRK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
提供了某些TRK抑制剂,其药物组合物以及使用方法。
Kinase Inhibitors And Methods Of Use Thereof
申请人:Groneberg Robert
公开号:US20090023795A1
公开(公告)日:2009-01-22
The compound of Formula (I) and pharmaceutically acceptable salts and prodrugs thereof are useful in the treatment and prevention of various disorders mediated by kinases.
式(I)化合物及其药用可接受的盐和前药在治疗和预防由激酶介导的各种疾病中非常有用。
Compounds and their uses 708
申请人:AstraZeneca AB
公开号:US08163905B2
公开(公告)日:2012-04-24
The present invention relates to pyrazinone derivatives of formula (I):
wherein R1, R2, R3, R4, R5, R6 and R7 are as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
The present invention relates to pyrazinone derivatives of formula (I):
wherein R
1
, R
2
, R
3
, R
4
, R
5
, R
6
and R
7
are as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
N-cyclopropyl-3-fluoro-5-[3-[[1-[2-[2- [(2-hydroxethyl)amino] ethoxy]phenyl] cyclopropyl] amino]-2-oxo-1 (2H)-pyrazinyl]-4-methyl-benzamide, or pharmaceutically acceptable salts thereof and their uses
申请人:AstraZeneca AB
公开号:US08299246B2
公开(公告)日:2012-10-30
The present invention relates to pyrazinone derivatives of formula (I):
wherein R1, R2, R3, R4, R5, R6 and R7 are as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.